Home > Boards > US OTC > Medical - Drugs > RegeneRx Biopharmaceuticals Inc (RGRX)

. Six out of 10 patients in the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
The Night Stalker  Member Profile
 
Followed By 500
Posts 67,623
Boards Moderated 4
Alias Born 05/25/08
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:19:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:16:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:16:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 4:18:12 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 10/16/2020 4:17:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 7:01:05 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/18/2020 6:06:31 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2020 4:05:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:20:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:18:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:16:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:13:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:12:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:10:22 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2020 9:47:02 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/30/2020 3:41:50 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/30/2020 3:40:44 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/20/2020 4:46:25 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/19/2019 6:01:20 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/19/2019 6:01:19 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:06:54 PM
The Night Stalker   Thursday, 05/14/20 11:40:08 AM
Re: subslover post# 256
Post # of 309 
. Six out of 10 patients in the RGN-259 treated group and 1 out of 8 patients in the placebo treated group achieved complete corneal healing in 4 weeks. In terms of the primary endpoint, "ratio of corneal wound healed patients after four weeks' administration", the statistical difference was slightly over 0.05 (p = 0.0656, Fisher's exact test), due to the limited number of patients in each group. When another statistical analysis method was used to analyze the same primary endpoint (Chi square test), there was statistical significance, p = 0.0400.




-mind fucked. what?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences